The price of Helius Medical Technologies Inc. (NASDAQ:HSDT) shares last traded on Wall Street fell -0.70% to $0.28.
Based on available information, 3 analysts follow Helius Medical Technologies Inc. (NASDAQ:HSDT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $1.00, we find $2.25. Given the previous closing price of $0.28, this indicates a potential upside of 703.57 percent. HSDT stock price is now -12.87% away from the 50-day moving average and -54.29% away from the 200-day moving average. The market capitalization of the company currently stands at $7.86M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Among analysts, 0 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $2.75 as their price target over the next twelve months.
With the price target of $20, Noble Capital Markets recently initiated with Outperform rating for Helius Medical Technologies Inc. (NASDAQ: HSDT)..
In other news, ANDREEFF DANE, President and CEO bought 80,041 shares of the company’s stock on Dec 16. The stock was bought for $19,946 at an average price of $0.25. Upon completion of the transaction, the President and CEO now directly owns 332,517 shares in the company, valued at $93104.76. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 23, President and CEO ANDREEFF DANE bought 89,300 shares of the business’s stock. A total of $27,835 was incurred on buying the stock at an average price of $0.31. This leaves the insider owning 308,003 shares of the company worth $86240.84. A total of 0.46% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HSDT stock. A new stake in Helius Medical Technologies Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $18,000. AYRTON CAPITAL LLC invested $4,000 in shares of HSDT during the first quarter. In total, there are 23 active investors with 5.20% ownership of the company’s stock.
A candlestick chart of Helius Medical Technologies Inc. (NASDAQ: HSDT) showed a price of $0.2821 on Thursday morning. During the past 12 months, Helius Medical Technologies Inc. has had a low of $0.20 and a high of $3.87. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 15.20, and a quick ratio of 14.70. The fifty day moving average price for HSDT is $0.3237 and a two-hundred day moving average price translates $0.6170 for the stock.
The latest earnings results from Helius Medical Technologies Inc. (NASDAQ: HSDT) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.12, beating analysts’ expectations of -$0.21 by 0.09. This compares to -$2.01 EPS in the same period last year. The company reported revenue of $0.2 million for the quarter, compared to $0.11 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 79.82 percent. For the current quarter, analysts expect HSDT to generate $260k in revenue.
Helius Medical Technologies Inc.(HSDT) Company Profile
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Leave a Reply